Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678054 · ClinicalTrials.gov registry record · Phase 2
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00678054 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT00678054, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
Interventions
- DRUG GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-04 |
| Est. Completion | 2015-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678054
The ClinicalTrials.gov registry entry for NCT00678054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GM-CSF is the first listed.
NCT00678054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678054 about?
NCT00678054 is a clinical study titled "Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)". This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
What is the current status of trial NCT00678054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-04. Estimated completion is 2015-10-23.
What interventions are being tested in trial NCT00678054?
The interventions under investigation include: GM-CSF (DRUG).
Who is sponsoring clinical trial NCT00678054?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.